NCT05778045 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Dufraing K, Van Casteren K, Breyne J, D'Haene N, Van Campenhout C, Vander Borght S, Zwaenepoel K, Rouleau E, Schuuring E, von der Thusen J, Dequeker E
Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders. BMC Cancer. 2022 Jul 6;22(1):736. doi: 10.1186/s12885-022-09798-5.
Kayser G
[Non-small cell lung cancer. New biomarkers for diagnostics and therapy]. Pathologe. 2015 Nov;36 Suppl 2:189-93. doi: 10.1007/s00292-015-0084-1. German.
Simeone JC, Nordstrom BL, Patel K, Klein AB
Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting. Future Oncol. 2019 Oct;15(30):3491-3502. doi: 10.2217/fon-2019-0348. Epub 2019 Sep 9.

Investigating Patients' Medical Study Experiences in Non-Small Cell Lung Cancer Clinical Trials to Identify Influencing Trends

Clinical trial NCT05778045 - References